Akeso, Inc. (AKESF)
| Previous close | 6.32 |
| Open | 6.32 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 6.32 - 6.32 |
| 52-week range | 5.00 - 6.45 |
| Volume | |
| Avg. volume | 1,970 |
| Market cap | 5.472B |
| Beta (5Y monthly) | 0.48 |
| PE ratio (TTM) | 19.15 |
| EPS (TTM) | 0.33 |
| Earnings date | 18 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Insider MonkeySummit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript
Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript May 1, 2024 Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06. SMMT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies […]
PR NewswireOral report | The positive interim analysis results from the Phase III clinical study of Akeso's Cadonilimab (PD-1/CTLA-4 BsAb) plus chemotherapy as first-line treatment for advanced gastric cancer presented at 2024 AACR
Akeso, Inc. (9926.HK) today announced that the positive interim analysis results from Phase III clinical study of Cadonilimab (PD-1/CTLA-4 BsAb) combined with XELOX (capecitabine plus oxaliplatin) as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (AK104-302/COMPASSION-15) were released presented in the form of oral presentation at the 2024 American Association for Cancer Research (AACR).
PR NewswireAkeso Announced the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-line Treatment of PD-L1 negative NSCLC
Akeso Inc. ("Akeso", 9926. HK) announced the enrollment of the first patient in the registrational Phase III clinical study comparing Cadonilimab (PD-1/CTLA-4 bispecific antibody) combined with chemotherapy versus Tislelizumab (PD-1 antibody) combined with chemotherapy in the first-line treatment for patients with PD-L1 negative (PD-L1 TPS＜1%) non-small cell lung cancer (NSCLC) (NCT05990127).
